Tonix Pharmaceuticals Aktie
WKN DE: A2N993 / ISIN: US8902605083
|
24.11.2025 13:37:49
|
Tonix Wins FDA Nod To Start Phase 2 Trial Of TNX-102 SL In Major depressive Disorder
(RTTNews) - Tonix Pharmaceuticals Holding Corp. (TNXP) said Monday that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for TNX-102 SL for the treatment of major depressive disorder (MDD) in adults.
The IND clearance allows the company to advance to the potentially pivotal Phase 2 HORIZON study, which will evaluate TNX-102 SL as a first-line monotherapy in adults with MDD.
Tonix Pharmaceuticals shares were down more than 2% in pre-market trading after closing at$16.10, up 2.94% on Friday.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Tonix Pharmaceuticals Holding Corp Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |